<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190517043609N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-01-25</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of intracavernous stem cell injection on the treatment of erectile dysfunction in diabetic patients</public_title>
      <acronym></acronym>
      <scientific_title>Clinical trial of the evaluation of the effect of intracavernous stem cell injection on the treatment of erectile dysfunction compared to control group  in diabetic patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/40988</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the block randomization method is used. Thus, of the 4 blocks, each block consisting of 2 intervention groups and 2 control groups, with the aim of progressing smoothly over the time of the groups, and this method continued until the sample size was completed 20 (including 10 Intervention group and 10 control group or 5 blocks of 4), Blinding description: In this study, the primary researcher (physician and data collector) is aware of the type of injectable material, but patients are unaware of the type of injectable material and are kept blind. Patients were divided into two groups of 10 intervention and control groups who were injected  randomized with stem cell or normal saline.</study_design>
      <phase>3</phase>
      <hc_freetext>Erectile dysfunction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group with local anesthesia, a tissue sample of about half a centimeter diameter without any need for suture was taken from each patient's oral mucosa and inserted into a solution of phosphate buffer containing antibiotics and amphotripsin (Exir Nano Sina co.) and immediately sent to the University's Stem Cell Center. Mucosal tissue transmitted 3 times with antibiotic buffered phosphate buffer and amphotripsin, divided into small parts under sterile conditions and at 4 ° C for 24 hours, adjacent to DMEM (Dulbeccos Modified Eagle Medium) (Neda Shimi Co.) medium containing 4 mg / mL of dysphasic enzyme and 3 mg / mL collagenase type 1 is placed. After 24 hours, the enzymum is slowly released and placed in a DMEM medium containing 15% FBS and 1% antibiotic (penicillin / streptomycin) (Exir Nano Sina co.) in a CO2 incubator (5%) with a humidity of 95% and a temperature of 37 °.After sticking and growing cells, which lasts for at least about 10 days, the adherent cells of the adipose trypsin enzyme are cultured again in the T25 flask after separation. Finally, the cells were examined for stem cell markers and purity by fluocytometric method and if th purity was more than 95%, the cells collected to be injected into the patient should be kept in the physician. After taking the required amount of stem cells   (60-50 million), the sample is sent to the Freeze room to the urological room and after melting with normal saline 0.9% diluted (up to 2 cc), into the intervention group in each corpus cavernosome is injected 1 cc. Then all patients in the intervention  group follow  by the International Index of Erectile Function (IIEF5) questionnaire and Doppler Sonography, Fasting Blood Sugar (FBS), and Glycated Hemoglobin (HBA1C) within three months and six months after injection. In addition, morning erection is recorded by patients every day. Intervention 2: Control group: In control group, 1 cc normal saline is injected in each Corpus cavernosum .Then all patients in the control group follow  by the IIEF5 questionnaire and Doppler Sonography, FBS, and HBA1C within three months and six months after injection. In addition, morning erection is recorded by patients every day.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahbobe Mirzaie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>St. Qarani Hospital Bahonar</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7613747181</zip>
        <telephone>+98 34 3222 1600</telephone>
        <email>mirzaeimahboubeh@yahoo.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahbobe Mirzaie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>St. Qarani Hospital Bahonar</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7613747181</zip>
        <telephone>+98 34 3222 1600</telephone>
        <email>mirzaeimahboubeh@yahoo.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Erectal dysfunction
Diabetes
Ages: 55-75 years</inclusion_criteria>
      <agemin>55 years</agemin>
      <agemax>75 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Hypertension
Hyperlipidemia
Obesity
Low testosterone
High prolactin
Hypothyroidism
Hyperthyroidism
Impaired Luteinizing Hormone ( LH)
Impaired Follicle Stimulating Hormone ( FSH)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Male erectile dysfunction</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group with local anesthesia, a tissue sample of about half a centimeter diameter without any need for suture was taken from each patient's oral mucosa and inserted into a solution of phosphate buffer containing antibiotics and amphotripsin (Exir Nano Sina co.) and immediately sent to the University's Stem Cell Center. Mucosal tissue transmitted 3 times with antibiotic buffered phosphate buffer and amphotripsin, divided into small parts under sterile conditions and at 4 ° C for 24 hours, adjacent to DMEM (Dulbeccos Modified Eagle Medium) (Neda Shimi Co.) medium containing 4 mg / mL of dysphasic enzyme and 3 mg / mL collagenase type 1 is placed. After 24 hours, the enzymum is slowly released and placed in a DMEM medium containing 15% FBS and 1% antibiotic (penicillin / streptomycin) (Exir Nano Sina co.) in a CO2 incubator (5%) with a humidity of 95% and a temperature of 37 °.After sticking and growing cells, which lasts for at least about 10 days, the adherent cells of the adipose trypsin enzyme are cultured again in the T25 flask after separation. Finally, the cells were examined for stem cell markers and purity by fluocytometric method and if th purity was more than 95%, the cells collected to be injected into the patient should be kept in the physician. After taking the required amount of stem cells   (60-50 million), the sample is sent to the Freeze room to the urological room and after melting with normal saline 0.9% diluted (up to 2 cc), into the intervention group in each corpus cavernosome is injected 1 cc. Then all patients in the intervention  group follow  by the International Index of Erectile Function (IIEF5) questionnaire and Doppler Sonography, Fasting Blood Sugar (FBS), and Glycated Hemoglobin (HBA1C) within three months and six months after injection. In addition, morning erection is recorded by patients every day.</i_keyword>
      <i_keyword>Control group: In control group, 1 cc normal saline is injected in each Corpus cavernosum .Then all patients in the control group follow  by the IIEF5 questionnaire and Doppler Sonography, FBS, and HBA1C within three months and six months after injection. In addition, morning erection is recorded by patients every day.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Erectile function. Timepoint: 3 and 6 months after the injection. Method of measurement: Questionnaire IIEF5 (International Index of Erectile Dysfunction Inventory) and Patient Statement and Color Doppler Sonography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>. Timepoint: . Method of measurement: .</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-13</approval_date>
        <contact_name>Ethics Committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>Havaniroz Street ,Ghadir Street Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
